Alzheimer’s loci: epigenetic associations and interaction with genetic factors

We explore the role of DNA methylation in Alzheimer's disease (AD). To elucidate where DNA methylation falls along the causal pathway linking risk factors to disease, we examine causal models to assess its role in the pathology of AD.

[1]  Manolis Kellis,et al.  Alzheimer's disease: early alterations in brain DNA methylation at ANK1, BIN1, RHBDF2 and other loci , 2014 .

[2]  D. Fardo,et al.  ABCA7 expression is associated with Alzheimer's disease polymorphism and disease status , 2013, Neuroscience Letters.

[3]  Nick C Fox,et al.  Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease , 2013, Nature Genetics.

[4]  Jason J. Corneveaux,et al.  Genetic susceptibility for Alzheimer disease neuritic plaque pathology. , 2013, JAMA neurology.

[5]  A. Gnirke,et al.  Charting a dynamic DNA methylation landscape of the human genome , 2013, Nature.

[6]  M. Owen,et al.  Increased expression of BIN1 mediates Alzheimer genetic risk by modulating tau pathology , 2013, Molecular Psychiatry.

[7]  R. Weksberg,et al.  Discovery of cross-reactive probes and polymorphic CpGs in the Illumina Infinium HumanMethylation450 microarray , 2013, Epigenetics.

[8]  Margaret A. Pericak-Vance,et al.  Novel late-onset Alzheimer disease loci variants associate with brain gene expression , 2012, Neurology.

[9]  J. Schneider,et al.  Overview and findings from the religious orders study. , 2012, Current Alzheimer research.

[10]  J. Schneider,et al.  Overview and findings from the rush Memory and Aging Project. , 2012, Current Alzheimer research.

[11]  Jason J. Corneveaux,et al.  A coding variant in CR1 interacts with APOE-ε4 to influence cognitive decline. , 2012, Human molecular genetics.

[12]  Jason J. Corneveaux,et al.  A genome-wide scan for common variants affecting the rate of age-related cognitive decline , 2012, Neurobiology of Aging.

[13]  D. Bennett,et al.  Alzheimer disease susceptibility loci: evidence for a protein network under natural selection. , 2012, American journal of human genetics.

[14]  Nick C Fox,et al.  Common variants in ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease , 2011, Nature Genetics.

[15]  D. G. Clark,et al.  Common variants in MS4A4/MS4A6E, CD2uAP, CD33, and EPHA1 are associated with late-onset Alzheimer’s disease , 2011, Nature Genetics.

[16]  F. Pasquier,et al.  Alzheimer risk associated with a copy number variation in the complement receptor 1 increasing C3b/C4b binding sites , 2011, Molecular Psychiatry.

[17]  Jason J. Corneveaux,et al.  CR1 is associated with amyloid plaque burden and age‐related cognitive decline , 2011, Annals of neurology.

[18]  Timothy J. Durham,et al.  "Systematic" , 1966, Comput. J..

[19]  J. Gilbert,et al.  Dementia Revealed: Novel Chromosome 6 Locus for Late-Onset Alzheimer Disease Provides Genetic Evidence for Folate-Pathway Abnormalities , 2010, PLoS genetics.

[20]  Sudha Seshadri,et al.  Genome-wide analysis of genetic loci associated with Alzheimer disease. , 2010, JAMA.

[21]  Lars Bertram,et al.  Genome-wide association studies in Alzheimer's disease. , 2009, Human molecular genetics.

[22]  L. Kiemeney,et al.  Corrigendum: Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer , 2009, Nature Genetics.

[23]  Nick C Fox,et al.  Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease, and shows evidence for additional susceptibility genes , 2009, Nature Genetics.

[24]  P. Bosco,et al.  Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease , 2009, Nature Genetics.

[25]  V. Pankratz,et al.  Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer's disease , 2009, Nature Genetics.

[26]  J. Schneider,et al.  The effect of social networks on the relation between Alzheimer's disease pathology and level of cognitive function in old people: a longitudinal cohort study , 2006, The Lancet Neurology.

[27]  E. Cochran,et al.  Apolipoprotein E ε4 allele, AD pathology, and the clinical expression of Alzheimer’s disease , 2003, Neurology.

[28]  H. J. Frank.  The Authors , 2002, Gov. Inf. Q..

[29]  D. Bennett,et al.  Apolipoprotein E epsilon4 allele, AD pathology, and the clinical expression of Alzheimer's disease. , 2003, Neurology.

[30]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .